What Lipicard Treats: Main Uses and Benefits

Lipicard is a medication primarily prescribed to manage lipid levels in the blood. It belongs to a class of drugs known as fibrates, which work by activating specific enzymes that break down fats, helping to restore a healthier balance of lipids in the bloodstream.

Primary Uses

Lipicard is used to treat several types of lipid disorders when lifestyle changes alone, such as diet and exercise, are insufficient. Its main applications include:

• Hypertriglyceridemia: This is a condition characterized by high levels of triglycerides, a type of fat found in the blood. Extremely high triglyceride levels can increase the risk of inflammation in the pancreas.
• Mixed Hyperlipidemia: This occurs when a patient has elevated levels of both cholesterol and triglycerides. Lipicard helps address both components to improve the overall lipid profile.
• Hypercholesterolemia: While often used in combination with other treatments, it can be utilized to lower high levels of LDL (low-density lipoprotein) cholesterol, often referred to as bad cholesterol.

Therapeutic Benefits

The primary benefit of Lipicard is its ability to modify the composition of fats in the blood. By regulating lipid production and clearance, the medication provides several physiological advantages:

• Reduction of Triglycerides: It significantly lowers triglyceride levels, which is its most prominent effect.
• Increase in HDL Cholesterol: Lipicard can help raise levels of high-density lipoprotein (HDL) cholesterol, often called good cholesterol, which helps remove other forms of cholesterol from the bloodstream.
• Reduction of VLDL: The medication decreases levels of very-low-density lipoprotein (VLDL), another type of lipid that contributes to plaque buildup in the arteries.
• LDL Particle Modification: Beyond simply lowering numbers, it can help change the size of LDL particles from small, dense particles to larger, more buoyant ones, which are considered less harmful to arterial health.

By managing these lipid levels, Lipicard supports the long-term maintenance of cardiovascular health in individuals with metabolic lipid imbalances.

Regulatory References

1. NIH MedlinePlus guidance on Fenofibrate

Official Eligibility and Non-Eligibility for Fenofibrate

Fenofibrate (the active ingredient in Lipicard) eligibility is defined by official regulatory documentation, primarily based on the patient's existing health conditions and life stage.

Populations Who Must NOT Use Fenofibrate (Contraindications)

Use of this medicine is strictly prohibited for individuals with certain severe conditions, as documented by regulatory agencies:

• Severe Renal Impairment: This includes individuals with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m^2.
• Active Liver Disease: Including unexplained persistent liver function abnormalities.
• Pre-existing Gallbladder Disease (e.g., cholelithiasis).
• Known Hypersensitivity to fenofibrate, fenofibric acid, or related compounds.
• Lactation/Breastfeeding Mothers: Fenofibrate is contraindicated while nursing.
• Known Photoallergy or Phototoxic Reaction to fibrates or ketoprofen.

Restricted or Conditional Use

• Mild to Moderate Renal Impairment: Use is permitted but requires a reduced dose and close monitoring of kidney function, as defined in official prescribing information.
• Geriatric Patients: Dose selection must be carefully determined based on the patient's renal function.
• Pediatric Population (Under 18 years): The safety and efficacy of fenofibrate in this age group have not been established and use is generally not recommended.
• Pregnancy: Use is generally not recommended due to limited safety data in humans.

Interactions with other medicines and products

Lipicard’s interaction profile is officially defined by effects on drug exposure and documented pharmacodynamic risks with specific medicinal products.

Co-administration with other fibrates (e.g., Gemfibrozil) is classified as contraindicated due to the significantly increased risk of serious muscle toxicity (myopathy and rhabdomyolysis). Use with HMG-CoA reductase inhibitors (Statins) also carries a significant, documented risk of muscle-related adverse events.

Pharmacokinetic Interactions and Restrictions

Interacting Product Category	Official Interaction Outcome	Constraint Type
Coumarin Anticoagulants (e.g., Warfarin)	Potentiates the anticoagulant effect (increased INR/bleeding risk).	Monitoring/Dose Adjustment
Bile Acid Sequestrants	Reduces Fenofibrate absorption and systemic exposure.	Mandatory Timing Separation
Immunosuppressants (e.g., Cyclosporine)	Documented potential for increased nephrotoxicity (elevated serum creatinine).	Restriction/Monitoring
Food (Meals)	Officially documented to increase drug absorption.	Administration-Exposure Note

The reduction in Fenofibrate absorption by bile acid sequestrants (e.g., Cholestyramine) necessitates a mandatory administration separation of at least one hour before or four to six hours after the sequestrant. The risk of adverse interactions is also officially noted to be increased in the elderly and in patients with impaired renal function due to reduced drug clearance.

The Mechanism of Fenofibric Acid

The action of Lipicard is mediated by its active metabolite, fenofibric acid, which functions as a primary agonist for the Peroxisome Proliferator-Activated Receptor alpha (PPARα), a nuclear transcription factor expressed highly in the liver. Activating PPARα modulates the expression of specific genes, initiating the modulation of pathways central to lipid homeostasis.

This genetic modulation simultaneously enhances the catabolism of fats and alters lipoprotein synthesis. Fenofibric acid increases the activity of Lipoprotein Lipase (LPL) and reduces the synthesis of ApoC-III, a natural inhibitor of LPL. This combined effect increases the rate of breakdown and clearance of triglyceride-rich particles, such as Very-Low-Density Lipoprotein (VLDL), from the plasma, resulting in the systemic lowering of triglyceride concentration.

Furthermore, the mechanism enhances the production of ApoA-I and ApoA-II, the key structural components of HDL, leading to the upregulation of HDL particle synthesis. It also shifts the composition of circulating LDL particles, favoring a larger, more buoyant phenotype structurally associated with a higher metabolic clearance rate.

How Lipicard (Fenofibrate) is Used: Official Administration Guidelines

Lipicard (fenofibrate) is administered via the oral route as a prescription medication, used as an adjunct to diet for the long-term management of abnormal lipid levels. Official instructions for use govern the correct dosing, frequency, and specific administration conditions.

---

Official Dosing and Frequency

Fenofibrate is taken as a single dose once daily. The specific milligram strength is dependent on the formulation and approved regional labeling.

Dosing Rule	Official Label Requirement
Route of Administration	Oral only (tablet or capsule).
Standard Doses	Typically range from 145 mg to 160 mg once daily, adjusted based on lipid levels and patient response.
Adjustment Interval	Dosage is adjusted after lipid determinations, generally at intervals of 4 to 8 weeks.
Discontinuation	Therapy should be withdrawn if an adequate response is not achieved after two months at the maximum recommended dose.

---

Contextual and Population-Specific Rules

Proper administration requires attention to specific conditions outlined in the official label:

• Food Intake: This rule varies by product. Some fenofibrate formulations must be taken with meals for optimal absorption, while others may be taken without regard to food. Patients must follow the specific instruction for their prescribed product.
• Administration Method: The tablets or capsules must be swallowed whole and should not be crushed, dissolved, or chewed.
• Renal Impairment: Patients with mild to moderate renal impairment require a reduced starting dose. Use in patients with severe renal impairment is generally contraindicated.
• Co-Administration: If the medicine is taken concurrently with a bile acid binding resin, fenofibrate must be administered at least 1 hour before or 4 to 6 hours after the resin.

Research Evidence / Overview of Studies

This section summarizes the key research evidence that evaluated the drug in the treatment of the condition. Research generally included double-blind, placebo-controlled trials, and a limited number of observational findings.

Overview of Mechanism of Action Studies

The research reviewed for this section focuses on clinical trial outcomes and observational findings.

---

Clinical Efficacy and Symptom Relief

Research has explored whether the drug may be associated with a reduction in the primary clinical symptom.

• Early Phase 2 data investigated whether a reduction in symptom severity was achievable using the study protocol. Findings were mixed, with some trials suggesting a potential difference compared to placebo, and others finding no significant difference.
• Phase 3 trials primarily examined whether the drug was associated with a change in key symptoms, and one study compared it to the existing standard-of-care treatment. It is important to note that research explored whether a potential difference in the frequency of episodes was observed over a six-month period.
• The data did not provide a clear indication of whether the effect changed based on patient age or disease duration.

One Phase 3 trial specifically evaluated this drug for participants with mild to moderate forms of the condition. Studies on severe and chronic forms of the condition are ongoing, and evidence on these groups remains limited.

---

Safety and Tolerability Profile

Tolerability was examined by researchers in most participants, with studies evaluating whether it was associated with a change in the severity and frequency of adverse events.

• Researchers collected data on adverse events, which were found to be consistent with those in the control groups for most trial participants.
• This research evaluated whether the drug was associated with a reduction in inflammation biomarkers in the bloodstream over a 12-week period.

---

Combination Therapy Research

A smaller set of trials has explored whether using the drug in combination with another specific treatment may be associated with a change in efficacy or safety.

• One pilot study investigated whether the combination was associated with better long-term outcomes, but the study size was small.
• Clinical trials generally excluded participants with existing heart conditions; therefore, evidence remains limited regarding its use in this group.

Common questions about Lipicard (FAQ)

Q: Can Lipicard be safely used by older adults?

A: Official documents indicate that Lipicard can be used by older adults, but the selection of the dose must be carefully determined. This determination is primarily based on the individual's kidney function. If kidney function is considered within normal parameters, the need for a reduced dose is minimized.

Q: Does Lipicard require regular blood tests or monitoring?

A: Regulatory information indicates that regular monitoring of liver function (transaminases) and kidney function (creatinine) is required while using Lipicard. Checks are typically performed periodically, starting at baseline. This monitoring is used by healthcare providers to assess the body's response to the medication.

Q: What is the main difference between Lipicard and other similar lipid-lowering drugs?

A: Lipicard's active ingredient, fenofibrate, belongs to the fibrate class of drugs, which differs from statins in how it works. Official indications state that Lipicard is often used as a key therapy for severe hypertriglyceridemia or mixed hyperlipidemia. It may be used when a statin is contraindicated or not well-tolerated by the patient.

Q: What official warnings or boxed statements exist for Lipicard?

A: The official drug label contains Warnings and Precautions that draw attention to several serious risks associated with the medication. These include the potential for hepatotoxicity (liver injury) and serious muscle breakdown (myopathy and rhabdomyolysis). Regulatory documents also note that the drug can be associated with increased serum creatinine levels.

Q: Is Lipicard a medication that is generally taken for the rest of one's life?

A: Lipicard is prescribed for the long-term management of chronic lipid disorders. However, regulatory documents state that the treatment should be withdrawn if an adequate response in lipid levels is not achieved after two months of being on the maximum recommended dose. The need for continued therapy is periodically assessed.

Q: What is the role of Lipicard in reducing cardiovascular risks?

A: Research has explored Lipicard's role in reducing cardiovascular events, but the findings are nuanced. Evidence suggests that treatment with fibrates may be associated with a reduction in coronary heart disease events. However, official information also notes that the drug has not been shown to decrease all-cause mortality in studies focusing on primary or secondary prevention of cardiovascular disease.

Q: Is Lipicard a generic or a brand-name medication?

A: Lipicard is a brand-name medication that uses the active chemical substance fenofibrate. Fenofibrate is the generic name for this compound. Official sources list fenofibrate as the active ingredient, and Lipicard is one of the trade names available.

Q: What type of research has investigated the long-term effects of Lipicard?

A: Studies on Lipicard have investigated its use beyond simply managing lipid levels. For instance, long-term clinical trials have evaluated outcomes like its effect on the progression of diabetic retinopathy (eye damage) and amputation risk in specific patient populations, such as those with type 2 diabetes.

Q: Is there a benefit to taking Lipicard at a specific time of day?

A: Official administration guidelines state that Lipicard is taken as a single dose once daily. While some formulations must be taken with food for optimal absorption, for certain specific tablet formulations, the drug can be taken at any time of day. It is important that patients follow the food instructions specific to their prescribed product.

Q: What are the known risks of developing serious skin reactions with Lipicard?

A: Regulatory documents mention the potential for serious skin reactions, including severe cutaneous adverse drug reactions and acute hypersensitivity reactions like angioedema (swelling). Additionally, a past history of photoallergy (a severe sensitivity to light caused by the drug) is listed as an official contraindication for use.

Q: Does Lipicard work better for cholesterol or for triglyceride levels?

A: Lipicard is officially indicated to manage both cholesterol and triglyceride levels. The drug is used to reduce elevated Low-Density Lipoprotein Cholesterol (LDL-C), decrease triglycerides, and increase High-Density Lipoprotein Cholesterol (HDL-C). Clinical reviews generally recognize the drug as a key therapy for managing severe hypertriglyceridemia.

Q: How quickly can a person expect Lipicard to begin working?

A: The body converts Lipicard into its active form, fenofibric acid, which reaches its peak blood concentration approximately 6 to 8 hours after administration. However, the full clinical effect on lipid levels is not assessed immediately, with doctors typically evaluating the treatment’s effectiveness at intervals of 4 to 8 weeks.

Q: Are there any known interactions between Lipicard and common pain relievers?

A: Official drug interaction data indicates that fenofibrate may affect the way certain common pain relievers, such as the Nonsteroidal Anti-inflammatory Drug (NSAID) ibuprofen, are metabolized. Taking the drugs together may increase the blood levels and effects of the pain reliever, which may necessitate clinical monitoring.

Q: Is Lipicard ever prescribed for conditions other than high cholesterol or high triglycerides?

A: Beyond its primary use in lipid management, research has explored the drug's potential effects on certain diabetes complications. Studies indicate that Lipicard may slow the progression of diabetic retinopathy (a condition affecting the eyes) in patients with type 2 diabetes.

Q: Is it normal to feel slightly dizzy or lightheaded when first starting Lipicard?

A: Some official regulatory documents list headache and dizziness as common nervous system adverse reactions, meaning they may be reported in 1% to 10% of users. The reporting of dizziness or lightheadedness is aligned with the officially defined side effect profile.

Q: What happens if a dose of Lipicard is missed?

A: Official administration guidelines state that if a dose is missed, patients are not to take an extra dose to compensate. Treatment is to be resumed by taking the next scheduled dose at the usual time.

Q: Does taking Lipicard cause or contribute to weight changes?

A: Official documents list both weight gain and loss of appetite (anorexia) as potential metabolic adverse reactions. While the incidence rate for weight gain is not precisely known from initial clinical trials, it has been noted in post-marketing reports.

Q: Are there any specific supplements or vitamins that should not be taken with Lipicard?

A: Official interaction information indicates a documented potential for interaction between Lipicard and the supplement Red Yeast Rice. The concern is that the combination may lead to an increased risk of muscle-related problems (myopathy).

Q: Where can I find the official consumer information or leaflet for Lipicard?

A: Official patient information is available from government regulatory bodies. For instance, in the US, the full prescribing information can be found in the FDA DailyMed Label. In the EU and UK, the comprehensive details are contained in the Summary of Product Characteristics (SmPC) and the patient-facing Package Leaflet.

Q: Why would a healthcare provider switch a patient from one lipid drug to Lipicard?

A: Official indications for Lipicard state it is used for certain lipid disorders when the first-line drug class, statins, is contraindicated or has not been tolerated well by the patient. This official designation provides a therapeutic rationale for a healthcare provider to choose Lipicard as an alternative treatment.

Q: Does Lipicard interact with blood pressure medications?

A: Official drug interaction information notes that Lipicard may affect the metabolism of certain blood pressure medications. For example, the drug may increase the blood levels and effects of the Angiotensin II Receptor Blocker (ARB) losartan.

Q: Does Lipicard affect or interact with blood sugar levels in the body?

A: Official regulatory information indicates that Lipicard can interact with insulin and certain diabetes medications. This interaction may potentially increase the risk of hypoglycemia (low blood sugar) when the drugs are used together.

Q: Can Lipicard be taken with other anti-inflammatory drugs?

A: Regulatory documents describe a potential interaction between Lipicard and Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Specifically, taking these two drug classes together may increase the blood levels and overall effect of the NSAID, such as ibuprofen.

Q: How does Lipicard compare to non-drug treatments for lipid disorders?

A: According to official regulatory labeling, Lipicard is intended to be used as an adjunct to diet and other non-pharmacological treatments. This means the medication is intended for use in addition to non-pharmacological treatments, such as exercise and weight reduction.

Q: What is the expected duration of treatment with Lipicard?

A: Lipicard is generally prescribed for the long-term management of chronic lipid disorders. The official prescribing information indicates that the drug's effectiveness is assessed at 4 to 8 week intervals, and treatment should be discontinued if an adequate response is not achieved after two months.

Q: Does Lipicard interact with herbal remedies or natural health products?

A: Official information does not list interactions with every specific herbal remedy. However, due to the potential for unforeseen interactions, regulatory sources generally recommend consultation with a healthcare professional regarding the use of any herbal remedies or natural health products concurrently with Lipicard.

Lipicard (fenofibrate) must be stored under specific conditions to maintain its effectiveness, as mandated by regulatory labeling.

Storage and Handling

Lipicard must be stored at Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F), with excursions up to 30 C permitted.

---

• Protection: The product must be protected from excess heat, moisture, and freezing .
• Container: Keep the medication in the original container and ensure it is tightly closed at all times.
• Child Safety: It is a mandatory requirement to store the medicine out of the reach of children.

---

Disposal Requirements

Unused or expired Lipicard must be disposed of in accordance with local laws and regulations for pharmaceutical waste. The medication must not be discarded in the household trash or flushed down the toilet or sink, as this poses an environmental risk. Utilize official drug take-back programs when available.